Highlight
- The live-attenuated intranasal RSV vaccine (RSVt) elicited robust neutralizing antibody responses in RSV-naive infants and toddlers.
- Both low-dose and high-dose vaccine regimens were generally well tolerated with no immediate systemic adverse events post vaccination.
- Solicited site and systemic reactions were slightly higher in vaccine groups compared to placebo but were predominantly mild and transient.
Study Background and Disease Burden
